|
Volumn 21, Issue 2, 2012, Pages 147-149
|
The RAF Inhibitor Paradox Revisited
|
Author keywords
[No Author keywords available]
|
Indexed keywords
B RAF KINASE;
CYTOTOXIC AGENT;
MITOGEN ACTIVATED PROTEIN KINASE;
PROTEIN KINASE INHIBITOR;
PROTEIN TYROSINE KINASE;
RAF PROTEIN;
VEMURAFENIB;
BONE MARROW SUPPRESSION;
CANCER CELL;
CANCER CHEMOTHERAPY;
CANCER RESISTANCE;
CANCER SURVIVAL;
CYTOTOXICITY;
DNA DAMAGE;
GENE MUTATION;
HUMAN;
KERATOACANTHOMA;
MELANOMA;
MOLECULARLY TARGETED THERAPY;
NONHUMAN;
ONCOGENE H RAS;
ONCOGENE N RAS;
ONCOGENE RAS;
OVERALL SURVIVAL;
PERSONALIZED MEDICINE;
PRIORITY JOURNAL;
SHORT SURVEY;
SIGNAL TRANSDUCTION;
SKIN CARCINOGENESIS;
SKIN CARCINOMA;
SQUAMOUS CELL CARCINOMA;
TREATMENT DURATION;
TREATMENT RESPONSE;
TUMOR GROWTH;
|
EID: 84856996617
PISSN: 15356108
EISSN: 18783686
Source Type: Journal
DOI: 10.1016/j.ccr.2012.01.017 Document Type: Short Survey |
Times cited : (20)
|
References (10)
|